Magrilan

Fluoxetine, the active ingredient in Magrilan, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral tablet for oral use. It is prescribed to treat depressive and anxiety‑related disorders in adult patients, helping to restore normal mood balance and reduce compulsive symptoms.

GNH USA supplies Magrilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution. The company ensures compliance with EU pharmacopeial specifications and offers comprehensive support for regulatory documentation.

Fluoxetine acts on the serotonergic pathway and is indicated for several psychiatric conditions.

Major depressive disorder: alleviates depressive symptoms and improves functional outcomes. Obsessive‑compulsive disorder: reduces obsessions and compulsive behaviors. Panic disorder: decreases frequency and severity of panic attacks. Bulimia nervosa: helps reduce binge‑eating and purging cycles. Premenstrual dysphoric disorder: eases mood swings and physical symptoms associated with the luteal phase.

Fluoxetine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Insomnia - Dry mouth - Diarrhea

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Serotonin syndrome - Severe allergic reaction (anaphylaxis) - Abnormal bleeding or bruising

Before initiating therapy, clinicians should consider several safety measures.

Assess psychiatric history: monitor for worsening depression or emergence of suicidal ideation, especially during early treatment. Avoid abrupt discontinuation: taper under medical supervision to reduce discontinuation syndrome. Use caution in patients with hepatic impairment: dose adjustment may be required. Consider drug interactions: review concomitant serotonergic agents. Store at ambient temperature: keep in original container, protect from moisture and light.

Fluoxetine interacts with several drug classes; careful assessment is required.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Tricyclic antidepressants: increased risk of cardiac toxicity. - Pimozide: can cause serious cardiac effects.

Moderate Interactions (Monitor Closely): - NSAIDs or anticoagulants: may increase bleeding risk. - CYP2D6 inhibitors (e.g., quinidine): may raise fluoxetine plasma levels.